
Sign up to save your podcasts
Or
Maria Luisa Pineda is the Co-founder and CEO of Envisagenics, which was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Given that there are over 30 million people in the United States who suffer from genetic diseases or cancer, which could be caused by mutations affecting RNA splicing, Envisagenics aims to accelerate the development of innovative therapeutic solutions for RNA splicing variants with the help of its AI platform.
Dr. Pineda has over a decade of experience as a biologist. She was awarded an endowment of $2 million dollars from the Goizueta Foundation and an NIH fellowship with the Minority Access to Research Careers program during her undergraduate training. She then went on to obtain her Ph.D. from the Watson School of Biological Sciences at Cold Spring Harbor Laboratory as an Arnold and Mabel Beckman graduate student and a William Randolph Hearst foundation scholar. On this episode, we discuss her experience in navigating the science startup world.
5
77 ratings
Maria Luisa Pineda is the Co-founder and CEO of Envisagenics, which was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Given that there are over 30 million people in the United States who suffer from genetic diseases or cancer, which could be caused by mutations affecting RNA splicing, Envisagenics aims to accelerate the development of innovative therapeutic solutions for RNA splicing variants with the help of its AI platform.
Dr. Pineda has over a decade of experience as a biologist. She was awarded an endowment of $2 million dollars from the Goizueta Foundation and an NIH fellowship with the Minority Access to Research Careers program during her undergraduate training. She then went on to obtain her Ph.D. from the Watson School of Biological Sciences at Cold Spring Harbor Laboratory as an Arnold and Mabel Beckman graduate student and a William Randolph Hearst foundation scholar. On this episode, we discuss her experience in navigating the science startup world.